Abstract:Background Hepatic stellate cells (HSCs) are the key drivers of fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), the fastest growing cause of hepatocellular carcinoma worldwide. HSCs are heterogenous, and a senescent subset of HSCs is implicated in hepatic fibrosis and HCC. Administration of anti-uPAR (urokinase-type plasminogen activator receptor) CAR T cells depletes senescent HSCs and attenuates fibrosis in murine liver injury models, including MASLD. However, the comprehensive features of senescent HSCs in MASLD, as well as their cellular ontogeny have not been characterized. Aims and Methods Our aims were to comprehensively characterize and define the origin of senescent HSCs in human and murine MASLD by integrating senescence-associated beta galactosidase activity with immunostaining, flow cytometry and single nuclear RNA-sequencing (snRNAseq). We integrated the immunohistochemical profile with a senescence score applied to snRNAseq data to characterize senescent HSCs, and mapped the evolution of uPAR expression in MASLD. Results Using pseudotime trajectory analysis, we establish that senescent HSCs arise from activated HSCs. While uPAR is expressed in MASLD, the magnitude and cell-specificity of its expression evolve with disease stage, such that in early disease, uPAR is more specific to activated and senescent HSCs, and in late disease, uPAR is also expressed by myeloid-lineage cells including Trem2 + macrophages and myeloid-derived suppressor cells. Furthermore, we identify novel surface proteins expressed on senescent HSCs in human and murine MASLD that could be exploited as therapeutic targets. Conclusions These data define features of HSC senescence in human and murine MASLD, establishing an important blueprint to target these cells as part of future antifibrotic therapy. LAY SUMMARY Hepatic stellate cells (HSCs) are the primary drivers of scarring in chronic diseases of the liver. As injury develops, a subset of HSCs become senescent; these cells are non-proliferative and pro-inflammatory, thereby contributing to worsening liver injury. Here we show that senescent HSCs are expanded in metabolic dysfunction-associated steatotic liver disease (MASLD) in humans and mice, and we trace their cellular origin from the activated HSC subset. We further characterize expression of uPAR (urokinase plasminogen activated receptor), a protein that marks senescent HSCs, and report that uPAR is also expressed by activated HSCs in early injury, and immune cells as liver injury advances. We have integrated high resolution single nuclei sequencing with immunostaining and flow cytometry to identify five other novel proteins expressed by senescent HSCs, including mannose receptor CD206, which will facilitate future efforts to clear senescent HSCs to treat fibrosis.

The senescent secretome drives PLVAP expression in cultured human hepatic endothelial cells to promote monocyte transmigration

IDDF2024-ABS-0445 PLOD2 Promotes Colorectal Cancer Liver Metastasis by Secreting Exosome to Mediate Macrophages Senescence

Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance

The senescence-associated secretome as an indicator of age and medical risk

Endothelial dysfunction in pathological processes of chronic liver disease during aging

Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease

The lysosomal proteome of senescent cells contributes to the senescence secretome

Senescent Endothelial Dysfunction is Attributed to the Up-Regulation of Sphingosine-1-phosphate Receptor-2 in Aged Rats

Impact of Senescent Cell-Derived Extracellular Vesicles on Innate Immune Cell Function

Exosomes Released from Senescent Cells and Circulatory Exosomes Isolated from Human Plasma Reveal Aging-associated Proteomic and Lipid Signatures

A plasma proteomic signature links secretome of senescent monocytes to aging- and obesity-related clinical outcomes in humans

Unbiased proteomic analysis of extracellular vesicles secreted by senescent human vascular smooth muscle cells reveals their ability to modulate immune cell functions

Endothelial Slc35a1 Deficiency Causes Loss of LSEC Identity and Exacerbates Neonatal Lipid Deposition in the Liver in Mice

Spatially resolved rewiring of mitochondria-lipid droplet interactions in hepatic lipid homeostasis.

T-cell senescence induced by peripheral phospholipids

Redox and mTOR-dependent regulation of plasma lamellar calcium influx controls the senescence-associated secretory phenotype

The role of liver sinusoidal endothelial cells in cancer liver metastasis.

LSECs Express Functional NOD1 Receptors: A Role for NOD1 in LSEC Maturation-Induced T Cell Immunity in Vitro

Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis

Regulation of Interstitial Lung Diseases by Pulmonary Endothelial Cells via PLVAP

Abstract 100: Omics Strategies To Identify Senescent Cells Mediating Extracellular Matrix Remodeling During Vascular Disease